NCT07140744View on ClinicalTrials.gov

A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

NANot yet recruitingINTERVENTIONAL

Enrollment

7,000

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Subjective Cognitive Impairment

Interventions

DIAGNOSTIC_TEST

P-tau217

Blood biomarker testing

OTHER

Standard of Care

Standard of care

Trial Locations (1)

10013

SiteRx Virtual Site, New York

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT07140744 - A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint | Biotech Hunter | Biotech Hunter